The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study.
Deirdre Jill Cohen
No relevant relationships to disclose
Paul J. Christos
No relevant relationships to disclose
Joseph A. Sparano
No relevant relationships to disclose
Hedy Lee Kindler
Consultant or Advisory Role - Genentech/Roche
Daniel Virgil Thomas Catenacci
No relevant relationships to disclose
Tanios B. Bekaii-Saab
Consultant or Advisory Role - Genentech; Sanofi
Sanaa Tahiri
No relevant relationships to disclose
Yelena Yuriy Janjigian
No relevant relationships to disclose
Michael K. Gibson
No relevant relationships to disclose
Emily Chan
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Lakshmi Rajdev
No relevant relationships to disclose
Susan Urba
No relevant relationships to disclose
James Lloyd Wade
No relevant relationships to disclose
Peter Kozuch
No relevant relationships to disclose
Erica Love
No relevant relationships to disclose
Katherine Vandris
No relevant relationships to disclose
Naoko Takebe
No relevant relationships to disclose
Howard S. Hochster
Consultant or Advisory Role - Genentech